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ABSTRACT
Background: The European Organization for the Research and Treatment
of Cancer Quality of Life Questionnaire (QLQ-C30) is a widely used
quality-of-life measure in oncology. The ability to translate QLQ-C30
responses into utility scores would further expand its use in medical
decision-making. The aims of this study were to: 1) map QLQ-C30
responses onto patient time trade-off utility scores; and 2) compare a
multiattribute approach to a global evaluation approach tomodeling utility
scores.
Methods: Two distinct approaches were applied to data from 1432 cancer
patients. The multiattribute approach used psychometric analysis and
expert input to select a subset of functioning and symptom scale items for
modeling. The second approach focused on global health and quality-of-
life items based on a conceptual model. Model selection criteria included
parsimony, statistical signiﬁcance and logical consistency of parameter
estimates, predictive accuracy, number of states described, and scale range.
Results: The optimal multiattribute model included nine variables for ﬁve
items from different scales, described 144 unique states, predicted values
ranging from 0.63 to 1.00, but it had poor predictive accuracy (cross-
validation pseudo-R2 = 0.056). The best-ﬁtting global approach-based
model described 24 unique states using eight indicators for two items from
one scale (plus a constant) and predicted values ranging from 0.17 to 1.00
(cross-validation pseudo-R2 = 0.127).
Conclusions: Multiattribute models produced a greater number of unique
predicted values, while global models exhibited more desirable statistical
properties and a wider range of values. The recommended models will
enable users to predict cancer patients’ utilities from existing and future
QLQ-C30 data sets.
Keywords: cancer, EORTC QLQ-C30, preferences, quality of life,
utility.
Introduction
One of the most widely used measures of health in clinical trials
speciﬁc to cancer is the European Organization for the Research
and Treatment of Cancer Quality of Life Questionnaire (EORTC
QLQ-C30) [1]. The QLQ-C30 is a multidimensional measure
with scales grouped into functioning, symptoms, and global
quality-of-life (QOL) categories. While the psychometric proper-
ties of the QLQ-C30 are well established, it was developed as a
proﬁle measure and was not designed to combine scale scores to
form a single summary score.
In contrast, the utility-based approach to health assessment
represents health as a single score, where dead is typically
assigned a value of 0 and best health is assigned a value of 1.
Utilities can be generated using a variety of elicitation methods
and perspectives: 1) elicited directly or generated indirectly
with utility measures; 2) from the perspective of patients or
community/general population (whether direct or indirect); and
3) elicited indirectly with a generic or cancer-speciﬁc measure
(whether from the perspective of patients or community). Direct
methods for utility elicitation include the standard gamble or the
time trade-off (TTO) [2]. Alternatively, utilities can be generated
in an indirect manner using measures such as the Health Utilities
Index Mark 3 [3] and the EQ-5D [4–6]. Indirect utility measures
involve self-completion of a health state classiﬁer system and the
subsequent application of a set of preference weights to obtain an
index-based single summary score. The algorithms derived for
most indirect measures are based on stated preferences for hypo-
thetical health states described by the health state classiﬁer
obtained from the community and/or general population. This
approach facilitates the calculation of quality-adjusted life-years
(QALYs), which are useful to compare the incremental beneﬁt of
cancer treatments and preventives in cost-effectiveness analyses
[7–13]. Several studies have developed utility-based algorithms
for QLQ-C30, typically mapping responses/scores from QLQ-
C30 onto EQ-5D scores [14–16].
A third approach is to obtain preferences for own health from
patients who have experienced cancer, and use statistical tech-
niques to map those preferences onto responses to a cancer-
speciﬁc proﬁle measure. Disease-speciﬁc measures may be more
sensitive to change than generic preference-based measures
because condition-speciﬁc measures are intended to capture
disease and treatment effects deemed important to patients
[17,18]. Dobrez et al. identiﬁed several factors that support the
usefulness of a cancer-speciﬁc, patient-based utility measure
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[16,19]. The ability to calculate QALYs from cancer patients’
responses to a disease-speciﬁc measure of functioning and QOL
may complement indirect utility measures that incorporate soci-
etal health preferences when examining the outcomes of clinical
trials, particularly when applied to privatized health-care systems
where most products and services are not funded by the general
population. In addition, understanding patient utilities for health
outcomes associated with different treatment options could
facilitate shared decision-making between clinicians and cancer
patients. Thus, the ability to generate a patient preference-based
score from the QLQ-C30 descriptive system could expand its use
in priority setting for both clinical and policy purposes.
Objectives
The aims of this study were to: 1) estimate a utility-based algo-
rithm by mapping QLQ-C30 responses onto patient utilities for
own health; and 2) compare a multiattribute approach to a
global evaluation approach to modeling utilities for own health.
Methods
Data Source
Data were drawn from a previously collected sample of patients
who participated in a prospective study at one of ﬁve academic
medical centers: Rush–Presbyterian–St. Luke’s Medical Center,
Robert H. Lurie Cancer Center of Northwestern University, Fox
Chase Cancer Center, Johns Hopkins Oncology Center, and
Medical College of Ohio [19]. Original selection criteria included
the ability to read and speak English, and a diagnosis of cancer or
human immunodeﬁciency virus/acquired immunodeﬁciency syn-
drome. In the current study, we focused on cancer patients and
excluded respondents who either failed to comprehend the TTO,
as judged by the interviewer, or did not complete the utility
assessment exercise and/or QLQ-C30 questionnaire.
Measures
In addition to providing demographic and clinical information,
the respondents were asked to complete several health status
questionnaires, including the QLQ-C30 version 2. QLQ-C30
version 2 is a 30-item, self-completed questionnaire with scales
measuring physical functioning (PF, ﬁve items), emotional func-
tioning (EF, four items), cognitive functioning (CF, two items),
role functioning (RF, two items), and social functioning (SF, two
items) [20]. A sixth-scale QOL includes two items that evaluate
overall QOL and health. The remaining items are divided among
multiitem symptom scales measuring nausea and vomiting (NV,
two items), pain (PA, two items), and fatigue (FA, three items),
and single-item scales that pertain to ﬁnancial concerns and other
somatic complaints. The two items on the QOL scale utilize a
7-point response scale ranging from “very poor” to “excellent.”
On QLQ-C30 version 2, PF items have dichotomized responses
(i.e., “yes” or “no”), and the other scales have four response
options ranging from “not at all” to “very much.” QLQ-C30
version 3 restructured the PF scale into items with four response
options.
Patient utility for their current health was elicited by an
interviewer using the TTO method [21]. A visual aid was used to
help patients understand the exercise. Initially, the patient was
asked whether his or her current health state was better than,
worse than, or equal to being dead. If the patient responded that
his or her current health state was worse than being dead, then
the utility for own current health was assigned a value of -1. If
the patient equated his or her own current health with being
dead, then the utility of own current health was assigned a value
of 0. Otherwise, the patient was asked to participate in an
exercise where he or she was offered a choice between living 1
year in his or her current health state, deﬁned as health over the
preceding 2 weeks, or a speciﬁed amount of time less than 1 year
in perfect health. The amount of time in perfect health was
incrementally lowered until the patient became indifferent to
living a year in his or her current health state and the speciﬁed
amount of time in perfect health.
Analytic Approach
Multiattribute and global approaches were employed to develop
models for predicting own health utilities from subsets of QLQ-
C30 items. The two approaches are described in detail in the next
sections.
Multiattribute approach. Initially, we sought to develop utility
mapping algorithms using a multiattribute approach. This
approach was applied in many utility mapping studies
[16,19,22–24]. The multiattribute approach is based on the
notion that an individual’s preference for a given health state is
determined by his or her perceived status in multiple domains of
health (e.g., physical, emotional, social). The approach follows
from multiattribute utility theory [25] and von Neumann–
Morgenstern expected utility theory [26]. Nevertheless, as opera-
tionalized in most research contexts, including utility mapping
studies, it is not fully consistent with MAUT, with the primary
inconsistency being a reversal in the parameters that are pre-
sumed to be known (or measured) and unknown (or estimated).
Because of this, the multiattribute approach has been labeled as
an empirical or “statistical inference” model [27]. That the
approach operates as MAUT in reverse does not invalidate its
use. On the contrary, it has been shown that models developed to
predict utilities using the multiattribute approach outperform
those that are more fully consistent with MAUT [27].
Global approach. The second approach to deriving preference-
based algorithms using QLQ-C30 items was based on a theory of
global health preference formation (GHPF) [28], where utility
mapping models were generated from the two items that com-
prised the QLQ-C30’s QOL scale. The conceptual basis of the
GHPF draws in part from reasoning coauthor JSW used to
explain ﬁndings in the US valuation of the EQ-5D health states
related to the relationship between respondent characteristics
and preferences for hypothetical health states [4]. Consistent
with the reasoning of Nord [29], the theory distinguishes
between the concepts of QOL and utility. The theory states that
the preference or utility (i.e., desirability) of a health state to an
individual is a function of the perceived QOL (i.e., satisfaction
and overall positive feelings) that the state imparts or would
impart, if presented in a hypothetical scenario. When asked to
value a health state, the individual evaluates multiple compo-
nents of health, or health in general, against his or her reference
standards. To the extent that the aggregate of these evaluations is
positive, the individual perceives the health state to be associated
with a higher level of (health-related) QOL. This perception
alone then determines the desirability of the health state. The
preceding evaluations are assumed to be uncorrelated with the
preference after accounting for perceived (health-related) QOL.
While the GHPF theory is a simple extension of the work of other
judgment theorists [30], it provides an alternative to the tradi-
tional view of preferences being formed directly as a consequence
of concurrent evaluations of multiple dimensions of health.
Further, the concept of rational decision-making based on a
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single global impression becomes appealing as the complexity of
the decision process grows (i.e., the number of dimensions to be
evaluated).
Item reduction. When applying the multiattribute approach,
some preliminary decision-making was necessary to identify a
manageable set of items for inclusion in the modeling phase.
Initially, we considered all of the items contained within the
QLQ-C30’s ﬁve functioning scales (i.e., EF, CF, PF, RF, and SF),
and PA and FA symptom scales while excluding the two global
QOL items. This approach was similar to the approach taken
by Brazier et al. [31] in selecting items for the SF-6D, which
excluded general health items. We desired to include at least one
item per scale in the models used to predict patient utilities.
Subsequent item selection decisions were based on criteria
informed by psychometric analyses. The ﬁrst criterion was item
feasibility (i.e., the extent to which each item was completed by
respondents) where items with a high rate of nonresponse were
considered unfeasible. The second criterion was the ability of
an item to represent its designated construct and discriminate
among subjects with different levels of that construct. The tech-
nical approach to evaluating this criterion is described in the next
paragraph. The third criterion was the correlational strength of
the relationship between items and own health utilities. This was
an important criterion because the ability of items to explain
utilities guided the selection of statistical models. Correlations
among items and between items and utilities were indexed using
Spearman’s r.
Item discrimination and construct representativeness were
evaluated using a combination of classical-test-theory-based and
item-response-theory-based approaches. Cronbach’s a and a-if-
item-deleted were used to gauge the contribution of each item to
the internal consistency of its scale [32]. The rating scale model
[33], an extension of the Rasch model for an ordered category
rating scale, was used to analyze item performance. This model
estimates three parameters: patient trait level (e.g., level of PF or
EF), each item’s location along the continuum of the trait scale
(from easiest to hardest to endorse), and category thresholds for
each response choice (with m - 1 thresholds for a scale having m
response choices) [34].
The ﬁt of the data to the rating-scale model was analyzed
using standard criteria (e.g., item misﬁt using a mean square
[MNSQ] outﬁt statistic). Misﬁt statistics are used to determine if
the items on a scale function together. If an item misﬁts the scale,
it implies that the item does not ﬁt well with the other items on
the scale and is a less desirable candidate to represent the scale.
MNSQ was derived by dividing the residual sum of squares (i.e.,
the sum of squared differences between observed and the
expected values) by the total number of respondents, and gauges
the discrepancy between observed and expected responses. The
MNSQ can be viewed as a c2 statistic divided by its degrees of
freedom [35]. An item was considered to misﬁt its scale if the
MNSQ was greater than 1.4 (indicating that the item was noisy
and not internally consistent with the other items) or less than
0.6 (indicating the item was redundant and did not contribute
unique information to the scale) [36]. Item difﬁculty, measured in
logits, was used to examine the dispersion of items across the
continuum of each attribute, where a higher score indicates
harder to endorse (i.e., worse health). This criterion was most
useful when choosing between multiple items from the same scale
to ensure they did not have a similar difﬁculty (i.e., level of health
attribute) along the scale continuum.
Model development and testing. Given the multimodal and
skewed distribution of utilities, models were ﬁt to the data using
median regression. The prediction of median (as opposed to
mean) utilities has theoretical justiﬁcation [37] and has been used
in similar studies [16]. The nonparametric bootstrap with 5000
repetitions was applied to derive standard errors for model
parameter estimates.
Item responses were treated as categorical and were recoded
as needed to ensure that a higher number indicated a better
response. One dummy variable was included as a model regres-
sor for each item response choice except for the highest (i.e., best)
response choice. The value of perfect health was estimated by the
intercept. No constraints were placed on the intercept when
ﬁtting any of the models. Any movement away from perfect
health was expected to result in a decline in utility (i.e., to be
associated with a negative parameter estimate). To be logically
consistent, parameter estimates were expected to decrease mono-
tonically with movement from the highest to lowest response
choice within each item.
Numerous model speciﬁcations were considered. Models
were distinguished primarily by item representation (multi-
attribute approach only) and number of estimable parameters.
Item response choices were collapsed to form a single response
category whenever parameter estimates for the associated
dummy variables were statistically indistinguishable. Response
categories were numbered from lowest (worst) to highest, with
the latter serving as the reference category. Wald tests of param-
eter estimates were used to determine if response categories
should be combined. A response category for which no param-
eter estimate is reported was combined with the next response
category (or categories) below it in the table. The decision to
combine response choices was not based on the results of the
rating scale analyses because the latter entailed different and
more restrictive assumptions than the median regression estima-
tor. In some instances, models were ﬁt while excluding patients
with extreme responses.
Models were evaluated based on parsimony (i.e., the number
of regressors), statistical signiﬁcance and logical consistency of
parameter estimates, number of unique predicted values and
states described, range of scale of the predictions, and predictive
accuracy. For the multiattribute approach, global items were not
included. The following statistics were derived to assess the pre-
dictive accuracy of each model: pseudo-R2, the sum of the abso-
lute deviations (SAD) between observed and predicted values, the
average and median absolute deviation between observed and
predicted values (AAD and MAD, respectively), as well as the
interquartile range (IQR) of these deviations, and the Spearman’s
rank-order correlation between observed and predicted values
(denoted as ry,yˆ). With the exception of the MAD and IQR, these
same statistics were computed following a 10-fold cross-
validation of each model. The cross-validation approach ran-
domly split the sample into 10 equally sized groups. Models were
ﬁt for each subsample after which various goodness-of-ﬁt indices
(e.g., pseudo-R2) were calculated. The indices were averaged over
the 10 subsamples to provide point estimates and measures of the
variability of those estimates. Any exclusion criteria that were
applied when ﬁtting a model in the pooled analytic sample were
also applied when performing the cross-validation.
The assumptions underlying the psychometric analyses used
to facilitate item reduction were more restrictive than those of the
median regression estimator used in the modeling phase. In the
process of developing and testing median regression models, we
determined that certain variables excluded from the modeling
phase outperformed others that were selected based on the
results of the psychometric analyses. Ultimately, for the EF scale,
we elected to examine every item from that scale in the multi-
attribute models.
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Models developed using the global approach necessarily
described fewer unique states than those developed using the
multiattribute approach. Consequently, observed, predicted, and
absolute residual values could be presented in a manageable
format for the global approach but not the multiattribute
approach. For each model developed using the global approach,
the weighted average and weighted median of the absolute
residuals were also derived.
Results
Sample Characteristics
From the initial sample of 2520 patients in the data set, 1614
(64.1%) were identiﬁed as suffering from one or more forms of
cancer. One hundred forty-six of these individuals (9.0%) failed
to complete the QLQ-C30 (87 [5.4%]), the TTO exercise (53
[3.3%]), or both (6 [0.3%]), while 34 patients (2.1%) did not
comprehend the TTO exercise. After excluding individuals with
missing data or comprehension problems, 1432 patients (88.7%)
remained for analysis. Descriptive statistics for the analytic
sample are presented in Table 1. The majority of patients
included in the analytic sample were white (82.3%) and male
(54.3%). By the time the study was conducted, 28% of patients
were in remission (i.e., had no evidence of cancer), while 30%
had distant metastases.
The mean (SD) TTO value for own current health was 0.79
(0.35). The 5th, 10th, 15th, 20th, 25th, 50th (median), and 75th
percentiles of the observed utility data were 0.06, 0.25, 0.50,
0.63, 0.75, 0.94, and 1.00, respectively. The distribution of own
health utilities was negatively skewed (skewness of -2.65) with
distinct modes at 0.83 (148 patients [10.3%]) and 1.00 (488
patients [34.1%]). Twenty-one patients (1.5%) valued their own
current health as worse than being dead, while 11 patients
(0.8%) equated their current health with being dead. Twenty-one
unique utility scores were recoded for patients included in the
analytic sample.
Item Reduction
No items were excluded from the modeling phase on the basis of
feasibility alone. All items exhibited a low rate of nonresponse
with 70 (4.9%) to 73 (5.1%) missing observations per item. The
scales exhibited a level of internal consistency that would be
considered sufﬁcient for group comparisons (i.e., Cronbach’s
a > 0.70) [32], with estimates of a ranging from 0.65 to 0.90
(Table 2). Only one item (PF5, which asks about the patient’s
ability to dress and wash him- or herself) was identiﬁed as
detracting from the internal consistency of its parent scale, which
otherwise contained items related to ambulation. Most items
were weakly correlated (r < 0.35) with utility for own health.
The strongest correlations of items with utilities involved QOL1
(the rating of overall health, r = 0.45) and QOL2 (the rating of
overall QOL, r = 0.42) (Table 2).
The rating scale model conﬁrmed the misﬁt of PF items PF4
and PF5. Four pairs of items were identiﬁed as measuring a
similar level of functioning on their respective scales: PF2/PF3,
RF1/RF2, CF1/CF2, EF2/EF3, and SF1/SF2. All scales demon-
strated ordered step measures with desirable item characteristic
curves for each level of response.
Based on the preceding results, eight items were prioritized
for the multiattribute approach modeling phase. These included
PF1, PF3, RF1, CF1, EF3, FA2, PA2, and SF2. Taken together,
these items were expected to contribute a maximum of 20 vari-
ables to the models (given m - 1 dummy variables for an item
with m response choices, 2 items ¥ 1 dummy variable + 6
items ¥ 3 dummy variables = 20 variables).
Model Development and Testing
Multiattribute approach. Five models were developed using the
multiattribute approach (models MA-1 to MA-5, Table 3).
Models MA-1 to MA-3 were informed by the item reduction
analysis, while models MA-4 and MA-5 were developed to maxi-
mize goodness of ﬁt. Models MA-1 and MA-2 included items
PF1, PF3, RF1, CF1, FA2, and PA2. Model MA-1 included EF2,
while model MA-2 included EF3. Both models yielded positive
parameter estimates for EF items. Model MA-3 excluded the EF
items and PF1, which was associated with a negligible parameter
estimate in models MA-1 and MA-2, and was the most parsimo-
nious model developed using the multiattribute approach.
All items on the EF, CF, PF, RF, SF, PA, and FA scales were
eligible for inclusion in models MA-4 and MA-5. The items
associated with negligible or logically inconsistent parameter
estimates in MA-1 and MA-2 (i.e., PF1 and the EF items) yielded
problematic estimates when included in MA-4 and MA-5.
Because these items had no discernable impact on model ﬁt, and
their associated parameter estimates were not statistically signiﬁ-
cant, a decision was made to exclude them. Compared with
models MA-1, MA-2, and MA-3, models MA-4 and MA-5
yielded a slight improvement in goodness of ﬁt as indexed by
pseudo-R2 (Table 4). Nevertheless, this improved ﬁt came at the
expense of parsimony and a further reduction in the statistical
signiﬁcance of parameter estimates.
Regardless of model speciﬁcation, few parameter estimates
were statistically signiﬁcant. There was little to distinguish
among the ﬁve models developed using the multiattribute
Table 1 Characteristics of analytic sample (n = 1432)
Characteristic N %
Gender
Male 753 52.6
Age (mean, SD) 56.9 (14.0)
Race/Ethnicity
White 1190 83.2
Black 191 13.3
Hispanic 42 2.9
Asian 17 1.2
Other 33 2.3
Type of cancer
Breast 250 17.5
Colon 170 11.9
Head and neck 163 11.4
Lung (nonsmall cell) 136 9.5
Lung (small cell) 35 2.4
Non-Hodgkin’s lymphoma 148 10.3
Prostate 189 13.2
Other known cancer (no HIV) 288 20.1
Unknown primary 15 1.0
Hodgkin’s disease 38 2.7
ECOG grade
0 409 28.6
1 384 26.8
2 460 32.1
3 164 11.5
4 12 0.8
Missing 3 0.2
Current extent of disease
None 396 27.7
Local 181 12.6
Regional 164 11.5
Distant metastasis 434 30.3
Not available 257 17.9
ECOG, Eastern Cooperative Oncology Group.
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approach in terms of performance and structure other than the
number of unique health states they described and their consis-
tency with the multiattribute framework (i.e., diversity of con-
structs represented). Given that the utility data were comprised
of only 21 unique values, it is reasonable to conclude that the ﬁve
models over-ﬁt the data (i.e., were more complex than needed to
explain the available information). With respect to consistency
with the multiattribute framework, each of the ﬁve models
included indicators for one or more items from the PF, RF, CF,
FA, and PA scales.
All of the models ﬁt the utility data to a similar extent
(Table 4). The difference between the overall and cross-
validation pseudo-R2 values, as a percentage of the overall
values, ranged from 19.8% (model MA-4) to 40.2% (model
MA-2) with an average percentage difference of 28.5%. Some ﬁt
indices (i.e., SAD, MAD, and ry,yˆ) appeared to favor MA-4 and
MA-5 over their rival speciﬁcations; however, the AAD varied
little among the ﬁve models. The most noticeable difference
among the models related to the number of unique health states
they described. The range of scale was similar between models,
with MA-2 having the greatest range, 0.564 to 1.061. The most
parsimonious model (MA-3) described 144 unique health states,
whereas the most comprehensive model (MA-5) described 2304
unique states of health. Models MA-1, MA-2, and MA-3 each
described a similar number of unique health states.
Global approach. Four models were developed using the global
approach (models G-1 to G-4, Table 5). When ﬁtting models G-1
andG-2, a small number of patientswho rated themselves as “very
poor” with respect to overall health (i.e., selected response option
1 for QOL1), but valued their own current health highly in the
TTO exercise were excluded from the sample in order to ensure
the logical consistency of parameter estimates.When ﬁttingmodel
G-1, patients were excluded if they provided a utility for own
current health that exceeded the unconditional median utility for
patients who selected response option 2 for QOL1 (i.e., a value in
excess of 0.625). Based on this criterion, 24 patients were
excluded from the sample. The median utility for own health
among the remaining patients who selected response option 1 was
0.375. Prior to ﬁtting model G-2, exploratory analyses were
performed to identify the maximum utility for own current health
that could be used to exclude patients while still obtaining mono-
tonically increasing parameter estimates for QOL1. Logically
consistent parameter estimates for QOL1 were not obtained with
threshold values exceeding 0.93. Subsequently, 11 patients who
selected response option 1 for QOL1 and provided a TTO value
for own health >0.93 were excluded. The median own health
utility for the remaining patients who selected response option 1
was 0.625. No patients were excluded from the analytic sample
when ﬁtting models G-3 and G-4.
Models G-3 and G-4 differed mainly with respect to the
category (categories) with which QOL1 response option 1 was
collapsed. When ﬁtting model G-3, QOL1 response option 1 was
collapsed with its neighbor, response option 2. Nevertheless, this
came at the expense of having to combine QOL2 response option
1 with its neighbors, response options 2 and 3. Only when QOL1
response option 1 was combined with response options 6 and 7
(as speciﬁed in model G-4) could a separate parameter be esti-
mated for QOL2 response option 1. The data-driven categoriza-
tion that resulted in model G-4 was expected to yield logical
inconsistencies in predicted values, although it offered a slightly
richer descriptive system (in terms of the number of estimated
parameters) than model G-3.
The results favored models G-1 and G-2 over models G-3 and
G-4. The item response categorization used when ﬁtting modelTa
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G-4 led to logical inconsistencies in predictions even though the
model’s parameter estimates were logically consistent. With
respect to the number of unique states described and the vari-
ability and range of predictions, model G-3 was inferior to
models G-1 and G-2. The criterion applied to exclude outliers
when ﬁtting model G-2 was more conservative than that applied
when ﬁtting model G-1. Additionally, model G-2 yielded a
parameter estimate for QOL1 response option 1 that was more
plausible than the estimate derived for model G-1 (although the
former was statistically insigniﬁcant). Conversely, model G-1
fared better than model G-2 in the cross-validation with a rela-
tive change in pseudo-R2 of just 5.2%. Ultimately, the choice
between model G-1 and model G-2 needs to be based on one’s
level of comfort with the exclusion of outliers from the estima-
tion sample. We would expect the two models to yield fairly
similar results in empirical applications, although model G-1
would be anticipated to yield a wider range of predicted utilities
than model G-2.
Each of the models yielded logically consistent parameter
estimates after excluding patients with extreme utilities and col-
lapsing redundant item response categories. With few exceptions
(i.e., QOL1 response option 1 for model G-2 and QOL2
response option 1 for model G-4), all parameter estimates were
statistically signiﬁcant at the 5% level. Fit statistics generally
favored model G-1 over its rivals. There was little to distinguish
among models G-2, G-3, and G-4 in terms of predictive accuracy.
The percentage difference between the overall and cross-
validation pseudo-R2 values ranged from 2.8% (model G-3) to
12.0% (model G-2) with an average percentage difference of
7.1%.
Table 6 presents comparisons of observed, predicted, and
absolute residual median values for the four models. For each
model, the data are sorted in descending order by observed value
and state, where the latter is deﬁned according to the combina-
tion of response options for QOL1 and QOL2. The mean abso-
lute state-level residuals for models G-1, G-2, G-3, and G-4 were
0.12, 0.14, 0.14, and 0.13, respectively. In general, the greatest
prediction errors were observed for states into which few patients
were classiﬁed based on their item responses. The predictions of
model G-1 ranged from 0.17 to 1.00, whereas those for the other
models ranged from 0.50 (G-2), 0.54 (G-4), or 0.63 (G-3) to
1.00. Models G-1 and G-2 described 24 unique states apiece.
Models G-3 and G-4 described considerably fewer unique states.
The predicted values for unique states were not necessarily dis-
tinct. Thus, the number of unique states, which was deﬁned by
the number of estimated parameters, set an upper bound for the
richness of the models’ descriptive systems.
Discussion
In recent years, a number of studies have been conducted to
develop utility mapping algorithms for questionnaires that were
not originally designed to serve as indirect utility measures
[16,38–40]. The current study sought to develop a model for
predicting cancer patients’ own health utilities from their
responses to the QLQ-C30 version 2. Two distinct lines of inves-
tigation were pursued. The ﬁrst involved the development of a
utility mapping algorithm via application of a multiattribute
approach to items selected using psychometric analyses, while
the second approach involved the use of a theory of GHPF to
guide the development of models for predicting utilities. All
models were ﬁt using a robust median regression estimator that
has been shown to exhibit beneﬁcial properties relative to mean-
based estimators [41]. A total of nine models were developed
using the two approaches. No single model clearly dominated.
Nevertheless, users may consider several factors (e.g., conceptual
Table 4 Predicted values and ﬁt statistics for mapping algorithms derived using the multiattribute approach
MA-1 MA-2 MA-3 MA-4 MA-5
Scales in model
Physical functioning PF1, PF3 PF1, PF3 PF3 PF2, PF3 PF2, PF3, PF4
Role functioning RF1 RF1 RF1 RF1, RF2 RF1, RF2
Cognitive functioning CF1 CF1 CF1 CF1 CF1
Emotional functioning EF2 EF3 — — —
Social functioning — — — SF2 SF2
Fatigue FA2 FA2 FA2 FA2 FA2
Pain PA2 PA2 PA2 PA2 PA2
Predicted values (for sample)
Mean (SD) 0.907 (0.104) 0.904 (0.111) 0.907 (0.105) 0.902 (0.107) 0.904 (0.108)
Median 0.955 0.962 0.962 0.940 0.953
Range 0.596–1.016 0.564–1.061 0.625–1.000 0.606–1.000 0.606–1.000
Unique states 1296 1296 144 1536 2304
Cross-validation
Pseudo-R2 0.058 0.049 0.056 0.073 0.073
(0.006, 0.099) (-0.037, 0.101) (0.021, 0.133) (0.028, 0.123) (0.009, 0.131)
SAD 25.279 25.275 25.220 24.871 24.627
(23.518, 26.645) (20.718, 30.271) (20.567, 30.654) (19.871, 28.476) (18.620, 32.530)
AAD 0.189 0.188 0.188 0.186 0.185
(0.173, 0.205) (0.158, 0.218) (0.147, 0.224) (0.151, 0.212) (0.137, 0.239)
ry,yˆ 0.402 0.403 0.406 0.424 0.425
(0.269, 0.481) (0.278, 0.511) (0.335, 0.520) (0.321, 0.520) (0.280, 0.520)
Overall ﬁt statistics
Pseudo-R2 0.083 0.082 0.082 0.091 0.092
SAD 246.788 245.219 247.082 243.956 242.296
AAD 0.184 0.183 0.184 0.182 0.182
MAD (IQR) 0.073 0.074 0.074 0.064 0.067
(0.021, 0.214) (0.023, 0.212) (0.023, 0.212) (0.020, 0.224) (0.019, 0.223)
ry,yˆ 0.421 0.421 0.424 0.438 0.443
AAD, average absolute deviation; IQR, interquartile range of absolute deviations; MAD, median absolute deviation; SAD, sum of the absolute deviations; ry,yˆ, Spearman rank-order correlation
between the observed and predicted values.
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Table 6 Observed, predicted, and absolute residual values for global approach-based models (cont)
G-1 G-2
State N Predicted Observed Abs. residual State N Predicted Observed Abs. residual
7, 7 138 1.000 1.000 0.000 7, 7 138 1.000 1.000 0.000
7, 6 9 1.000 1.000 0.000 7, 6 9 1.000 1.000 0.000
7, 5 2 1.000 0.583 0.417 7, 5 2 1.000 0.583 0.417
6, 7 62 1.000 1.000 0.000 6, 7 62 1.000 1.000 0.000
6, 6 243 1.000 1.000 0.000 6, 6 243 1.000 1.000 0.000
6, 5 25 1.000 1.000 0.000 6, 5 25 1.000 1.000 0.000
5, 7 31 0.939 0.991 0.052 5, 7 31 0.939 0.991 0.052
5, 6 117 0.939 0.939 0.000 5, 6 117 0.939 0.939 0.000
5, 5 185 0.939 0.939 0.000 5, 5 185 0.939 0.939 0.000
6, 4 5 0.917 1.000 0.083 6, 4 5 0.917 1.000 0.083
4, 7 4 0.917 0.625 0.292 4, 7 4 0.917 0.625 0.292
4, 6 35 0.917 0.939 0.022 4, 6 35 0.917 0.939 0.022
4, 5 77 0.917 0.917 0.000 4, 5 77 0.917 0.917 0.000
5, 4 27 0.856 0.939 0.083 5, 4 27 0.856 0.939 0.083
4, 4 97 0.834 0.834 0.000 4, 4 97 0.834 0.834 0.000
3, 6 5 0.834 0.939 0.105 3, 6 5 0.834 0.939 0.105
3, 5 25 0.834 0.834 0.000 3, 5 25 0.834 0.834 0.000
6, 3 2 0.833 0.427 0.407 6, 3 2 0.833 0.427 0.407
2, 6 3 0.792 0.750 0.042 2, 6 3 0.792 0.750 0.042
2, 5 5 0.792 0.939 0.147 2, 5 5 0.792 0.939 0.147
6, 2 1 0.791 0.500 0.291 6, 2 1 0.791 0.500 0.291
6, 1 1 0.791 1.000 0.209 6, 1 1 0.791 1.000 0.209
5, 3 2 0.772 0.396 0.377 5, 3 2 0.772 0.396 0.377
3, 4 44 0.751 0.750 0.001 3, 4 44 0.751 0.750 0.001
4, 3 16 0.750 0.750 0.000 4, 3 16 0.750 0.750 0.000
5, 2 1 0.730 0.939 0.209 5, 2 1 0.730 0.939 0.209
2, 4 8 0.709 0.438 0.272 2, 4 8 0.709 0.438 0.272
4, 2 3 0.708 0.250 0.458 1, 7 1 0.709 0.625 0.084
4, 1 2 0.708 0.595 0.114 1, 5 3 0.709 0.375 0.334
3, 3 75 0.667 0.750 0.083 4, 2 3 0.708 0.250 0.458
3, 2 11 0.625 0.625 0.000 4, 1 2 0.708 0.595 0.114
3, 1 3 0.625 0.625 0.000 3, 3 75 0.667 0.750 0.083
2, 3 21 0.625 0.625 0.000 1, 4 1 0.626 0.166 0.460
2, 2 27 0.583 0.625 0.042 3, 2 11 0.625 0.625 0.000
2, 1 5 0.583 0.166 0.417 3, 1 3 0.625 0.625 0.000
1, 7 1 0.375 0.625 0.250 2, 3 21 0.625 0.625 0.000
1, 5 3 0.375 0.375 0.000 2, 2 27 0.583 0.625 0.042
1, 4 1 0.292 0.166 0.126 2, 1 5 0.583 0.166 0.417
1, 3 0 0.208 — — 1, 3 1 0.542 0.917 0.375
1, 2 2 0.166 -0.188 0.354 1, 2 5 0.500 0.750 0.250
1, 1 12 0.166 0.271 0.105 1, 1 21 0.500 0.625 0.125
Mean (SD) 0.738 (0.235) 0.697 (0.295) 0.124 (0.149) 0.787 (0.149) 0.734 (0.246) 0.140 (0.159)
Median 0.791 0.750 0.068 0.791 0.750 0.083
WA/WM 0.893/0.939 0.896/0.939 0.020/0.000 0.894/0.939 0.899/0.939 0.022/0.000
Range 0.166–1.000 -0.188 to 1.000 0.000–0.458 0.500–1.000 0.166–1.000 0.000–0.460
Unique states (values) 24 (21) 24 (20)
G-3 G-4
State N Predicted Observed Abs. residual State N Predicted Observed Abs. residual
7, 7 138 1.000 1.000 0.000 7, 7 138 1.000 1.000 0.000
7, 6 9 1.000 1.000 0.000 7, 6 9 1.000 1.000 0.000
7, 5 2 1.000 0.583 0.417 7, 5 2 1.000 0.583 0.417
6, 7 62 1.000 1.000 0.000 6, 7 62 1.000 1.000 0.000
6, 6 243 1.000 1.000 0.000 6, 6 243 1.000 1.000 0.000
6, 5 25 1.000 1.000 0.000 6, 5 25 1.000 1.000 0.000
5, 7 31 0.939 0.991 0.052 1, 7 3 1.000 0.962 0.038
5, 6 117 0.939 0.939 0.000 1, 5 4 1.000* 0.375 0.625
5, 5 185 0.939 0.939 0.000 5, 7 31 0.939 0.991 0.052
6, 4 5 0.917 1.000 0.083 5, 6 117 0.939 0.939 0.000
4, 7 4 0.917 0.625 0.292 5, 5 185 0.939 0.939 0.000
4, 6 35 0.917 0.939 0.022 6, 4 5 0.917 1.000 0.083
4, 5 77 0.917 0.917 0.000 4, 7 4 0.917 0.625 0.292
5, 4 27 0.856 0.939 0.083 4, 6 35 0.917 0.939 0.022
4, 4 97 0.834 0.834 0.000 4, 5 77 0.917 0.917 0.000
3, 6 5 0.834 0.939 0.105 1, 4 2 0.917* 0.583 0.334
3, 5 25 0.834 0.834 0.000 5, 4 27 0.856 0.939 0.083
6, 3 2 0.833 0.427 0.407 4, 4 97 0.834 0.834 0.000
6, 2 1 0.833 0.500 0.333 3, 6 5 0.834 0.939 0.105
6, 1 1 0.833 1.000 0.167 3, 5 25 0.834 0.834 0.000
2, 6 3 0.792 0.750 0.042 6, 3 2 0.833 0.427 0.407
2, 5 5 0.792 0.939 0.147 6, 2 1 0.833 0.500 0.333
1, 7 3 0.792 0.962 0.170 1, 3 1 0.833* 0.917 0.084
1, 5 4 0.792 0.375 0.417 1, 2 9 0.833* 0.917 0.084
5, 3 2 0.772 0.396 0.377 2, 6 3 0.792 0.750 0.042
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basis, range of scale) when choosing one of the available speci-
ﬁcations for use in empirical applications.
Individual-speciﬁc covariates (e.g., age, sex, stage of diagno-
sis, treatment phase, geographic region) were not included as
regressors in any of the models. While these variables might have
improved the ﬁt of some or all of the models, their inclusion as
regressors would have reduced the generality of the models to
external data sources. Although pseudo-R2 values for the models
tended to be poor, they were comparable in magnitude to ﬁt
indices reported in other utility mapping studies conducted for
cancer-speciﬁc questionnaires [16,19].
Among the multiattribute models, MA-3 presents the best
option for those users who desire a utility mapping algorithm
based on the multiattribute framework. MA-3 had the most
statistically signiﬁcant indicators, and it was the most parsimo-
nious model with the best goodness of ﬁt other than the models
speciﬁcally designed for that purpose, MA-4 and MA-5.
Models MA-4 and MA-5 were developed using a methodology
that was ad hoc in the sense that it ignored the results of the
prescribed rating scale analyses. These models provided a slight
improvement in ﬁt over the other models at the expense of
reduced parsimony and an increased risk of over-ﬁtting the
data.
Each of the ﬁve models based on the multiattribute
approach, MA-1 to MA-5, included indicators for one or more
items from the PF, RF, CF, FA, and PA scales, but only MA-1 and
MA-2 included items from the EF scale. If one believes in the
validity of multiattribute utility theory and the QLQ-C30
descriptive system, better health states should be associated with
lower predicted utilities than worse health states with minimal
logically inconsistent predicted utilities. Whether or not the EF
scale should be represented in a utility mapping algorithm
depends on one’s belief in the validity of the multiattribute
approach, as well as the notion that preferences for health are
determined by EF as measured by the QLQ-C30. The perceived
beneﬁt of including EF scale items in models of own health
utilities must be weighed against the logical inconsistency of their
parameter estimates because the latter would be expected to
contribute to logically inconsistent predicted utilities. On an
interpretive level, this logical inconsistency implies worse EF is
associated with a more desirable health state when controlling
for other components of health. If true, as TTO utilities were
directly elicited for own health from cancer patients, results
suggest that emotionally distressed cancer patients may be rela-
tively risk averse (i.e., less willing to trade-off any time in present
health for shorter time in better health). Further research into this
curious result is warranted in future studies.
Among the global approach-based models, G-1 satisﬁed
almost all of the criteria better than models G-2 to G-4, which
was accomplished by design by excluding sample respondents
who contributed logically inconsistent responses. Although it is
intuitive that there should be a wide range of scale of model
predictions, there were limited data to support this conjecture.
The fact that 10% of the analytic sample had own health utilities
that were 0.25 would appear to favor model G-1, which
yielded 3 of 24 states (12.5%) with predicted utilities <0.25.
Nevertheless, the crudeness of procedure used to elicit utilities in
this study renders interpretation of the lower end of the predicted
range difﬁcult because all values for states worse than dead were
set to -1.
The choice between model MA-3 and model G-1 should be
guided mainly by the conceptual framework to which one sub-
scribes. If one believes in the validity of the multiattribute frame-
work, then model MA-3 would be the most appropriate
speciﬁcation. On the other hand, those who prefer the idea that
preferences are formed on the basis of a global impression or
evaluation would be counseled to choose model G-1.
Regardless of whether or not outliers were excluded from the
analytic sample, models developed using the global approach
provided a better ﬁt for patients’ own health utilities than did
models developed using the multiattribute approach. Con-
versely, the multiattribute models appeared to describe more
Table 6 Continued
G-3 G-4
State N Predicted Observed Abs. residual State N Predicted Observed Abs. residual
5, 2 1 0.772 0.939 0.167 2, 5 5 0.792 0.939 0.147
3, 4 44 0.751 0.750 0.001 5, 3 2 0.772 0.396 0.377
4, 3 16 0.750 0.750 0.000 5, 2 1 0.772 0.939 0.167
4, 2 3 0.750 0.250 0.500 3, 4 44 0.751 0.750 0.001
4, 1 2 0.750 0.595 0.156 6, 1 1 0.750 1.000 0.250
2, 4 8 0.709 0.438 0.272 4, 3 16 0.750 0.750 0.000
1, 4 2 0.709 0.583 0.126 4, 2 3 0.750 0.250 0.500
3, 3 75 0.667 0.750 0.083 1, 1 24 0.750* 0.688 0.063
3, 2 11 0.667 0.625 0.042 2, 4 8 0.709 0.438 0.272
3, 1 3 0.667 0.625 0.042 4, 1 2 0.667 0.595 0.073
2, 3 21 0.625 0.625 0.000 3, 3 75 0.667 0.750 0.083
2, 2 27 0.625 0.625 0.000 3, 2 11 0.667 0.625 0.042
2, 1 5 0.625 0.166 0.459 2, 3 21 0.625 0.625 0.000
1, 3 1 0.625 0.917 0.292 2, 2 27 0.625 0.625 0.000
1, 2 9 0.625 0.917 0.292 3, 1 3 0.584 0.625 0.041
1, 1 24 0.625 0.688 0.063 2, 1 5 0.542 0.166 0.376
Mean (SD) 0.810 (0.125) 0.758 (0.233) 0.137 (0.156) 0.831 (0.129) 0.758 (0.233) 0.131 (0.167)
Median 0.792 0.834 0.083 0.833 0.834 0.063
WA/WM 0.896/0.939 0.900/0.939 0.023/0.000 0.901/0.939 0.900/ 0.939 0.021/0.000
Range 0.625–1.000 0.166–1.000 0.000–0.500 0.542–1.000 0.166–1.000 0.000–0.625
Unique states (values) 15 (13) 19 (15)
States are deﬁned according to response choices for QOL1, QOL2. The number of unique states described by the ith model is Si = (pi + 1) ¥ (qi + 1), where pi and qi index the number of
estimated parameters for QOL1 and QOL2, respectively, for the ith model.The number of unique values predicted by the ith model is equal to Si minus the number of duplicate predictions.
Logically inconsistent predictions are denoted with (*).
SD, standard deviation;WA, weighted average;WM, weighted median.
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unique states than did models developed using the global
approach. Nevertheless, the importance of the latter difference is
questionable in light of concerns about multiattribute models
over-ﬁtting the data.
If a more elegant utility elicitation procedure had been used
and produced more unique data values, then it is conceivable
that the multiattribute models would have fared somewhat
better against the models developed using the global approach.
Consequently, the adequacy of QOL1 and QOL1 would be
expected to diminish with increases in the complexity of (i.e.,
variation in) observed own health utilities. This represents a
measurement problem and does not invalidate the GHPF theory
because items measuring individual components (not determi-
nants) of QOL could be used in place of QOL1 and QOL2.
Nevertheless, such items are not included in current versions of
the QLQ-C30.
While the overall ﬁt of models developed using the global
approach was reasonable compared to other studies, the models
provided an inadequate ﬁt for states observed infrequently in the
data. This is sometimes problematic for utility mapping studies,
as only a very small subset of respondents may self-report the
worse levels of health for certain domains [21]. Conversely,
studies of individual preferences for hypothetical health states are
usually designed to ensure a sufﬁcient sampling of different levels
of health for each domain or construct of interest.
The present study differs from most mapping studies in that
the utilities were obtained from patients for own health states
rather than using scores obtained either directly from the general
population for hypothetical health states using a health state
classiﬁer system (e.g., SF-6D) [22], or indirectly mapped onto
scores from an existing preference-based measure like EQ-5D
[16]. The utilities in the data set were collected from a relatively
large cohort of cancer patients with a variety of different types of
cancer who were represented in crudely similar proportions to
their prevalence (e.g., a higher proportion of respondents had
breast, colorectal, and prostate cancer patients) relative to the
other cancers. Thus, in some respects, the algorithms derived in
the present study may be more broadly applicable to patients
with different types of cancer. In contrast, respondents in other
mapping studies had speciﬁc subtypes of cancer (e.g., pancreatic
cancer [15] or metastatic hormone-refractory prostate cancer
[16]).
As noted previously, the data analyzed in this study were
collected using version 2 of the QLQ-C30. The EORTC has
developed a new version of the instrument, version 3, and is
currently advocating its use. Models developed using the global
items are still applicable to QLQ-C30 version 3 because no
changes were made to the response structure of the QOL items.
Because of the differences between versions 2 and 3, none of the
multiattribute models could be applied to data collected using
QLQ-C30 version 3 without risking the introduction of bias.
One might be able to justify applying model MA-3 to data
collected using QLQ-C30 version 3 after collapsing responses to
PF3 from four to two categories. Nevertheless, the validity of this
approach would require further investigation.
The data used in our research were taken from the same data
set used by Dobrez et al. to map cancer patients’ utilities onto
responses to the functional assessment of cancer therapy-general
[19]. While our modeling approach differed in important ways
from the approach used by Dobrez et al., the two studies pro-
duced similarly complex utility mapping algorithms that, with
one exception, yielded predictions spanning a similar range.
Therefore, to some degree one may view the ﬁndings of Dobrez
et al. as providing a sensitivity analysis of our own results (and
vice versa).
Conclusions
We provide several plausible utility mapping algorithms for the
QLQ-C30. Two distinct approaches were employed to develop
an algorithm to predict cancer patients’ own health utilities from
responses to version 2 of the QLQ-C30. Researchers conducting
future utility mapping studies may ﬁnd one or both of these
approaches to be useful. We found that the global models per-
formed better than the multiattribute models. Nevertheless, the
selection of a particular algorithm for use in any empirical appli-
cation should be guided by end users’ beliefs about how health
state preferences are formed. The utility algorithms are distinct
from other published algorithms in that they are cancer speciﬁc
rather than generic, and based on utilities assigned by patients for
experienced health states rather than the general population for
hypothetical health states. Thus, they may be most relevant to
decision-makers who want clinical care or resource allocation
decisions to be informed by cancer patient preferences for health
states. Future studies are necessary to determine whether cancer
patients’ own health utilities predicted from responses to the
QLQ-C30 are more sensitive to meaningful changes in clinical
status than population-based utilities predicted from responses to
the EQ-5D or similar indirect measures. In addition, further
studies are needed to examine the advantages and pitfalls of
using global models to derive utilities in speciﬁc conditions and in
general populations.
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